Stratus Versus Cirrus OCT in AMD
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Information provided by:
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
ClinicalTrials.gov Identifier:
NCT00568191
First received: December 4, 2007
Last updated: NA
Last verified: December 2007
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Cirrus OCT provides due to the spectral domain technology a 2-fold resolution than Stratus OCT generated in a comparable amount of time. Due to this higher resolution the retinal surface and the retinal pigment epithelium can be identified more clearly, a significantly reduced number of algorithm failures is expected
| Condition |
|---|
|
Age-Related Macular Degeneration Choroidal Neovascularization |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Reliability of Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT |
Resource links provided by NLM:
Genetics Home Reference related topics:
age-related macular degeneration
MedlinePlus related topics:
Macular Degeneration
U.S. FDA Resources
Further study details as provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:
Primary Outcome Measures:
- Number of algorithm failures assessed by Stratus OCT versus Cirrus OCT in the horizontal central line [ Time Frame: only 1 examination ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Number of algorrithm failures in Stratus versus Cirrus OCT assessed in the whole scan [ Time Frame: 1 examination ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | October 2007 |
| Estimated Study Completion Date: | December 2007 |
| Groups/Cohorts |
|---|
|
1
retinal thickness program Stratus OCT software 4.0
|
|
2
retinal cube 200x200 program of Cirrus OCT
|
Eligibility| Ages Eligible for Study: | 55 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients aged > 55 years of either sex presenting with age-related macular degeneration
Criteria
Inclusion Criteria:
- Age>55 years
- Age-related macular degeneration
Exclusion Criteria:
- Not consented patients
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00568191
Please refer to this study by its ClinicalTrials.gov identifier: NCT00568191
Contacts
| Contact: Ilse Krebs, MD | +43171165 ext 94607 | Ilse.Krebs@wienkav.at |
Locations
| Austria | |
| Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery | Recruiting |
| Vienna, Austria, A1030 | |
| Contact: Ilse Krebs, MD +43171165 ext 4607 Ilse.Krebs@wienkav.at | |
| Principal Investigator: Ilse Krebs, MD | |
Sponsors and Collaborators
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Investigators
| Principal Investigator: | Ilse Krebs | Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery |
More Information
No publications provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Prof Susanne Binder, The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery |
| ClinicalTrials.gov Identifier: | NCT00568191 History of Changes |
| Other Study ID Numbers: | EK 06-007-VK1 |
| Study First Received: | December 4, 2007 |
| Last Updated: | December 4, 2007 |
| Health Authority: | Austria: Ethikkommission |
Keywords provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:
|
Age-related macular degeneration choroidal neovascularization Stratus OCT Cirrus OCT |
Additional relevant MeSH terms:
|
Choroidal Neovascularization Macular Degeneration Neovascularization, Pathologic Choroid Diseases Eye Diseases |
Metaplasia Pathologic Processes Retinal Degeneration Retinal Diseases Uveal Diseases |
ClinicalTrials.gov processed this record on February 27, 2015